Day Traders Tag icon

×
Wednesday, Canada-based NanoVation Therapeutics announced a multi-year partnership with Novo Nordisk A/S (NYSE:NVO) to advance the development of novel genetic medicines targeting cardiometabolic and rare diseases. The partnership combines NanoVation Therapeutics' proprietary long-circulating lipid nanoparticle (lcLNP) technology for RNA delivery to cells outside the liver with Novo Nordisk's expertise in cardiometabolic and rare disease R&D and clinical translation. Also Read: Ozempic Maker Novo Nordisk Touts Encouraging Data From New Obesity Pill Showing Double Weight Loss Compared To Wegovy. Under the agreement, Novo Nordisk and NanoVation will collaborate on two lead programs to develop base-editing therapies for certain ...


In The news